drugset
drugset / Trial / NCT04278885

Lanadelumab in FXII-associated Cold Autoinflammatory Syndrome (FACAS)

NCT04278885 ↗

Phase 2 Unknown 4 enrolled Charite University, Berlin, Germany Shire International GmbH · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, exploratory, proof-of-concept, single-center, open-label pilot study to assess the effects and safety of Lanadelumab in patients with FXII-associated cold autoinflammatory syndrome (FACAS).

Timeline

Start
2020-10-05
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanadelumab Monoclonal antibody 300 mg Subcutaneous

Indications

F12-associated cold autoinflammatory syndrome